Pfizer Inc: (NYSE: PFE)

$29.40

0.24 (0.82%)

Volume 159,805,408

Jun 18 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		29.03 - 29.45
	
		52wk Low - High
		22.00 - 31.15
	
		Previous Close
		29.16
	
		Avg. Volume
		67,159,736
	
		Industry
		LARGE CAP PHARMA
	
		Market Cap
		206.84 B
	
		Div - Yield
		0.96 - 3.29
	
		Beta
		0.73
	
		P/E (F1)
		13.20
	
		Current Year Est.
		2.21
	
		Quarterly Earnings ESP 
		-3.57%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		178 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 06/14/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            13.20
                        
                            PEG Ratio
                            3.16
                        
                            Current Year Est.
                            2.21
                        
                            Current Quarter Estimate
                            0.56
                        
                            Most Accurate Estimate
                            0.54
                        
                            Earnings ESP 
                            -3.57%
                        
                            Next Earnings Report Date
                            08-06-2013
                        
                            EPS Last Year
                            2.16
                        
                            Expected Earnings Growth
                            4.18%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.   
Full PFE Company Report

 Analyst Report on PFE

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
PFE Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.56	0.54	2.21	2.32
Number of Estimates	6	6	10	8
Low Estimate	0.50	0.53	2.11	2.19
High Estimate	0.58	0.57	2.27	NA
Year Ago EPS	0.62	0.53	2.19	2.21
EPS Growth	-10.22%	2.20%	0.87%	4.86%

More PFE Estimates

Average Earnings Estimates for PFE

EPS Growth for PFE

Industry Analysis

Name	Symbol	Previous Close
PFIZER INC	PFE	29.16
NOVO-NORDISK AS	NVO	161.70
ABBOTT LABS	ABT	36.89
ABBVIE INC	ABBV	43.01
ALLERGAN INC	AGN	101.48
ASTRAZENECA PLC	AZN	50.97
BRISTOL-MYERS	BMY	46.44
GLAXOSMITHKLINE	GSK	52.74
JOHNSON & JOHNS	JNJ	85.63
LILLY ELI & CO	LLY	52.36

Sector:Medical>> Industry:LARGE CAP PHARMA

COMPARE TICKER vs. Its Peers

Zacks Commentary

Ariad's Iclusig in GIST Phase II Study

Jun 18, 2013

Apremilast Data Presented by Celgene

Jun 14, 2013

Lilly Alzheimer's Study Terminated

Jun 14, 2013

$2.15B Settlement for Pfizer's Protonix

Jun 13, 2013

CRL for AVEO/ALPMY's Tivozanib

Jun 12, 2013

Encouraging Data on Novartis Candidate

Jun 10, 2013

Positive Data on Novartis' Afinitor

Jun 07, 2013

Pfizer in $635 Million Deal

Jun 07, 2013

More PFE Zacks Commentary

Financials

EPS TTM	2.16
Sales	58,986
Net Income	15,526
Price/Earnings	13.50
Price/Book	2.53
Price/Cash Flow	8.91
Price/Sales	3.59

More PFE Financials

News

"Pay-For Delay" Was Fun While It Lasted - TheMotleyFool

Jun 18, 2013

Big Pharma`s Intellectual Property Blues - TheMotleyFool

Jun 18, 2013

Fitch: At-Risk Launch Settlement Could Pressure Teva's Ratings - Close-Up Media

Jun 18, 2013

Fitch: At-Risk Launch Settlement Could Pressure Teva's Ratings - Close-Up Media

Jun 18, 2013

Global Kidney Cancer Drugs Market 2013 Report - M2

Jun 18, 2013

InSite Vision to jointly file patent infringement lawsuit against Mylan Pharmaceuticals along with Merck - M2

Jun 18, 2013

Interesting Similarities Among 2013`s Top-Performing ETFs - Benzinga

Jun 18, 2013

Market Maker Surveillance Report. PFE, C, JPM, INTC, MSFT, AQUM, Bullishly Biased Price Friction For Monday, June 17th 2013 - M2

Jun 18, 2013

See All News Stories on PFE

Broker Recommendations

Current ABR	1.54
ABR (Last Week)	1.54
# of recs in ABR	13
Average Target Price	30.50
Industry Rank by ABR	178 out of 265
Rank in Industry	2 out of 15

More PFE Broker Recommendations

Day Low - High	29.03 - 29.45
52wk Low - High	22.00 - 31.15
Previous Close	29.16
Avg. Volume	67,159,736
Industry	LARGE CAP PHARMA
Market Cap	206.84 B
Div - Yield	0.96 - 3.29
Beta	0.73
P/E (F1)	13.20
Current Year Est.	2.21
Quarterly Earnings ESP	-3.57%

P/E (F1)	13.20
PEG Ratio	3.16
Current Year Est.	2.21
Current Quarter Estimate	0.56
Most Accurate Estimate	0.54
Earnings ESP	-3.57%
Next Earnings Report Date	08-06-2013
EPS Last Year	2.16
Expected Earnings Growth	4.18%

Username: Password:

Remember me [?]

Pfizer Inc: (NYSE: PFE)

$29.40

0.24 (0.82%)

Volume 159,805,408

Jun 18 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:LARGE CAP PHARMA

Zacks Commentary

Financials

News

Broker Recommendations